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Abstract
The loss of p16 is a signature event in Human Papilloma Virus (HPV)-negative head and neck squamous cell carcinoma
(HNSCC) that leads to increased Cyclin Dependent Kinase 4/6 (CDK) signaling. Palbociclib, a CDK4/6 inhibitor, is active
for the treatment of a subset of HNSCC. In this study, we analyzed patient response data from a phase I clinical trial of
palbociclib in HNSCC and observed an association between prior cisplatin exposure and CDK inhibitor resistance. We
studied the effects of palbociclib on cisplatin-sensitive and -resistant HNSCC cell lines. We found that while palbociclib
is highly effective against chemo-naive HNSCC cell lines and tumor xenografts, prior cisplatin exposure induces
intrinsic resistance to palbociclib in vivo, a relationship that was not observed in vitro. Mechanistically, in the course of
provoking a DNA damage-resistance phenotype, cisplatin exposure upregulates both c-Myc and cyclin E, and
combination treatment with palbociclib and the c-Myc bromodomain inhibitor JQ1 exerts a synergistic anti-growth
effect in cisplatin-resistant cells. These data show the beneﬁt of exploiting the inherent resistance mechanisms of
HNSCC to overcome cisplatin- and palbociclib resistance through the use of c-Myc inhibition.

Introduction
Head and neck squamous cell carcinomas (HNSCC) are
a collection of diseases, diagnosed in ~59,000 people per
year, and responsible for ~12,000 deaths in the U.S.
annually. The majority of HNSCC incidence (~40,000
cases) is attributed to tobacco exposure and smoking1.
The molecular epidemiology of HNSCC is strongly
determined by geographic location and anatomic subsite
that dictates the genetics of these tumors. Among viralrelated cancers, oropharynx cancers are increasingly
caused by human papillomavirus (HPV)2,3. HPVassociated tumors usually lack mutations or deletions in
cell cycle inhibitory proteins because the cell cycle

Correspondence: Brian A. Van Tine (bvantine@wustl.edu)
1
Washington University in St. Louis School of Medicine, St. Louis, MO, USA
2
Medical College of Wisconsin, Milwaukee, WI, USA
Full list of author information is available at the end of the article.
These authors contributed equally: Anthony M. Robinson, Richa Rathore
Edited by M. Herold

machinery is disrupted by the E6 and E7 viral proteins. In
contrast, tobacco-associated cancers acquire the capacity
for unrestrained proliferation by a near ubiquitous loss of
the tumor suppressor protein p16 (CDKN2A)4. p16 loss is
tightly linked to smoking-related cancer and it serves as
the biomarker for HPV-negative HNSCC5,6. In normal
cells, p16 restrains the activity of the cyclin-dependent
kinases 4 and 6 (CDK4/6). In HNSCC tumor cells, the loss
of p16 confers CDK4/6 activity, resulting in hyperphosphorylation of the retinoblastoma protein (Rb)7,8. Thus
far, there has been a distinct lack of therapies targeting the
genetic alterations of HNSCC, with the epidermal growth
factor receptor (EGFR) monoclonal antibody cetuximab
being the only targeted agent to be approved9. Cisplatin
chemotherapy remains the most effective ﬁrst-line agent
in recurrent and metastatic disease10. The epidemiologic
and molecular data surrounding CDK4/6 and Rb in
HNSCC suggest that CDK4/6 has promise as a therapeutic target in HNSCC.
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Entry from G1 into S-phase is driven by the enzymatic
activity of CDK4 and CDK6, which complex with one of
the regulatory D-type cyclins (D1, D2, or D3)11. CDK4/6cyclin D complexes promote hyperphosphorylation of Rbfamily proteins (Rb1, RbL1/p107, and RbL2/p130), of
which Rb1 is the best characterized12. Phosphorylation of
Rb disables its capacity to function as a transcriptional
repressor that sequesters the cell-cycle regulatory E2F
transcription factor. These proteins are required to activate the S- and M-phase transcriptional programs needed
for successful cell cycle progression. The importance of
CDK4/6 and cyclin D1 in passing this checkpoint is
highlighted by the observation that CDK4 and cyclin D1
are highly ampliﬁed in many tumors13. Moreover, CDK4
and cyclin D1 have been shown to be required for
tumorigenesis in several experimental models14–17.
CDK4/6 activity results in the activation of several genes,
including cyclin E1 and cyclin E218. Cyclin E is the regulatory subunit of CDK2, which further phosphorylates
and completely inactivates Rb, leading to E2F release and
cell cycle progression19,20. The functional relationship
between the various CDK proteins is complex, and their
biochemical roles have not been good predictors of their
genetic function, as elucidated by mouse knockout studies21. Surprisingly, mice are able to survive inactivation
of both CDK2 and CDK4 genes, and mammalian cell
cycles with normal S-phase kinetics can be completed
successfully in their absence21,22. These ﬁndings indicate
the likelihood of signiﬁcant functional redundancies in the
cell cycle machinery, a probability which explains some of
the difﬁculties observed with targeting cell cycle kinases.
Therapeutic targeting of the G1-S transition has been a
longstanding goal of oncologic pharmaceutical development. Early CDK inhibitors, such as ﬂavopiridol, were
generally non-speciﬁc across multiple CDKs and exhibited limited activity in clinical trials23,24. Palbociclib
(PD00332991) is unique as a selective inhibitor of CDK4/
6, and is the ﬁrst approved CDK inhibitor for the treatment of cancer25. Its original indication was for use in
endocrine-resistant breast cancer. However, clear biomarkers of response to palbociclib treatment have yet to
be identiﬁed, and neither ampliﬁcation of CCND1 (coding
for cyclin D1) or loss of p16 were deﬁnitively linked to
response in breast cancer trials26,27. The lack of associated
biomarkers that predict palbociclib response has fostered
a great interest in the identiﬁcation of mediators of
therapy response and resistance. To date, pre-clinical
models have offered some elucidation of potential determinants of palbociclib response; primarily, heightened
CDK2 and cyclin E levels that have been observed in
breast and pancreatic cancer models, have been shown to
confer resistance to the drug28,29. Cyclin E is ampliﬁed in
breast cancer and is overexpressed in pancreatic cancer30.
Although cyclin E is not ampliﬁed or genetically altered in
Ofﬁcial journal of the Cell Death Differentiation Association
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HNSCC, other inputs, such as EGFR, may elevate CDK2cyclin E activity in this disease4.
An interesting feature of targeted therapy development
(including immunotherapies) is that initial clinical testing
usually takes place in the metastatic setting, in patients
who have been exposed to cytotoxic chemotherapy. The
utility of this strategy has some limitation, as it is well
established that chemotherapy can alter the genetic landscape of residual tumors31–33. Whole-genome sequencing
of leukemia cells has revealed that chemotherapy can
result in the selection of aggressive clones that resist
therapy34. Exposure to cisplatin can also alter the genome,
resulting in a platinum-speciﬁc signature that includes an
increase in a speciﬁc mutational proﬁle (increased C > A
mutations)35. Importantly, cisplatin is an essential component of both curative and palliative therapy for HNSCC.
In this light, we investigated and now report the effects of
cisplatin exposure on palbociclib sensitivity in both the
pre-clinical and clinical settings in HNSCC. We demonstrate that cisplatin exposure confers intrinsic crossresistance to the CDK4/6 inhibitor palbociclib. Using
in vitro and in vivo analyses, we identify the underlying
mechanism of this resistance, and demonstrate a clinically
relevant mechanism for overcoming this resistance.

Results
Patients with cisplatin-resistant HNSCC show a reduced
response to palbociclib treatment

We previously reported the Phase I results of palbociclib
combined with cetuximab in a cohort of either cetuximab- (6/9) or platinum- (4/9) refractory patients36. Palbociclib demonstrated activity in both platinum-sensitive
and -resistant patients, but while the mean time to progression (TTP) in platinum-sensitive patients was
188.6 days, the mean time to progression in patients with
platinum-resistant disease was shorter at 91 days (Fig. 1a)
(p = 0.0201)37. As this data encompasses a patient set
treated with a combination of cetuximab and palbociclib,
this difference in TTP does not immediately distinguish
the effects of palbociclib versus cetuximab in the pattern
of response and resistance. However, cetuximab has
activity (Fig. 1b) in cisplatin-resistant patients (patient
characteristics presented in Fig. 1c)38, and therefore we
considered that cisplatin exposure may be altering the
efﬁcacy of palbociclib speciﬁcally.
Cisplatin resistance predicts palbociclib resistance in mice
bearing HNSCC cell-line-derived xenografts

To investigate the effects of cisplatin exposure on CDK4/
6 inhibition in HNSCC, we identiﬁed palbociclib-sensitive
HNSCC cell lines. We grew three commonly used HPVnegative, p16-negative cell lines (Cal27, SCC1, and SCC25)
as xenografts in immunodeﬁcient mice to ~200 mm3 in size
and then treated the mice with palbociclib by oral gavage39.
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Fig. 1 Patients with cisplatin-resistant HNSCC show a reduced response to palbociclib treatment. a Percent progression-free survival as shown
by mean time to progression based on cisplatin resistance status in a Phase I clinical trial of palbociclib. Cisplatin-resistant patients (n = 4), cisplatinsensitive patients (n = 5). Statistics stated are by Fisher’s exact test, error bars represent SD. b Mean time to progression highlighting disease response
to palbociclib + cetuximab. c Patient characteristics for Phase I clinical trial (NCT02499120)

Tumor xenografts from each of the three cell lines
responded signiﬁcantly and nearly uniformly with evident
tumor regression and complete loss of measurable tumor
within ~10 days of treatment (p < 0.0001) (Fig. 2a, c, e).
These data point to a dependency on CDK4/6 in these p16negative HNSCC tumor lines.
Next, we determined the IC50 of cisplatin in vitro in
these cell lines, and subsequently increased this value by
serial exposure of cells to increasing levels of cisplatin
using a previously published protocol40 (Supplemental
Fig. 1A). Having established cisplatin-resistant cell lines,
we sought to identify changes to the activity of palbociclib,
but saw no consistent relationship between cisplatin
exposure and palbociclib sensitivity in vitro, as seen by
IC50 measurement (Supplemental Fig. 1B). We show that
palbociclib treatment caused a signiﬁcant increase in
number of cells in G1, suggesting cell cycle arrest in both
cisplatin-resistant cells and parental cells (Supplemental
Fig. 2A–C). We also showed that with palbociclib
Ofﬁcial journal of the Cell Death Differentiation Association

treatment, there was a signiﬁcant increase in cells accumulating in G2/S in cisplatin-resistant cells compared to
parental lines, and a corresponding decrease in cells
accumulating in G1 in cistplain-resistant cells compared
to parental lines (Supplemental Fig. 2D–F). However,
measuring DNA damage repair capacity in these cells by
comet assay showed that cisplatin-exposed cells exhibited
signiﬁcantly diminished comet tails 1- and 4-h after
radiation when compared to parental cells, indicating
higher levels of DNA repair41–43 (Supplemental Fig. 3A,
B). Interestingly, Cal27 cisplatin-resistant lines show
increased comet tails compared to parental at baseline,
suggesting decreased DNA repair in this line (Supplemental Fig. 3A, panel 1). This correlates with data
showing that Cal27 has an overly active CDK4 pathway
due to truncating mutations in SMAD444, suggesting that
the biological effects of cisplatin treatment, including
increased DNA damage, could still be apparent in the
resistant cell lines.
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Fig. 2 Cisplatin resistance predicts palbociclib resistance in mice bearing HNSCC cell-line-derived xenografts. Tumor growth curves of paired
cisplatin-sensitive (a, c, e) and cisplatin-resistant (b, d, f) HNSCC cell lines, treated for 10 days with palbociclib (70 mg/kg, daily). N = 5 mice per group
and measurements are summarized as mean ± SEM. (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001, by Student’s t-test)

Targeted therapies may have differential effects in vitro
as compared to in vivo45. Therefore, we tested the effects
of cisplatin resistance in vivo by growing the parental and
cisplatin-resistant (cisplatin-R) cells as xenografts in mice.
Cisplatin-resistant cells were grafted into mice and
allowed to form tumors ~200 mm3 in size, then treated
with palbociclib. These tumors grew through treatment
unabated at an equivalent rate to untreated tumors in all
cell lines (Fig. 2b, d, f). These data indicate that cisplatin
exposure causes resistance to palbociclib in palbociclibnaïve cells. Moreover, evidence of resistance is restricted
to tumorigenic growth in vivo, and does not seem to
extend to the two-dimensional tissue culture
Ofﬁcial journal of the Cell Death Differentiation Association

environment. To highlight the validity of this effect
in vivo, we performed CD31 staining on sections of
treated tumors, and found that palbociclib treatment
caused a notable decrease in angiogenesis by CD31 when
compared to vehicle control, implicating the microenvironment of the tumor as having a role in the efﬁcacy
of palbociclib (Supplemental Fig. 4A, B).
Assessment of palbociclib pharmacodynamics in vivo
shows signiﬁcant CDK4 suppression

To investigate mechanisms of resistance to palbociclib,
we identiﬁed the directed targeting and suppression of
CDK4 by palbociclib. CDK4 phosphorylates Rb at serine
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Fig. 3 Assessment of palbociclib pharmacodynamics in vivo. a Representative immunoblots of Ser780 phospho-Rb, total Rb, and actin for tumor
cell lysates obtained from xenografts of parental cell-line control (gray) and 48 h of palbociclib treatment (red). b Corresponding cisplatin-resistant
cell-line control (black) and 48 h of palbociclib treatment (blue). c Quantiﬁcation by photo densitometry was performed on bands using Image Lab
Software, and the ratio of phospho-Rb/total Rb was calculated. All quantiﬁcation is presented as mean ± SD. (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001,
****p ≤ 0.0001, by Student’s t-test)

780, allowing for hyperphosphorylation of Rb. Tumor
lysates were taken from control and cisplatin-resistant
tumors, and levels of Rb phosphorylation at serine 780
were analyzed by immunoblot (Fig. 3a, b). We showed a
decrease of phosphorylated Rb relative to total Rb in
cisplatin-sensitive cells treated with palbociclib (Fig. 3c).
In cisplatin-resistant cell lines, two of the three also
showed a decrease in phosphorylated Rb relative to total
protein (Fig. 3c), with CAL27 showing a lack of response
due to SMAD4-related palbociclib resistance44. We
therefore show that palbociclib treatment is decreasing
phosphorylation of Rb, regardless of cisplatin-sensitivity
status. Based on these results, we concluded that palbociclib adequately suppresses its target, CDK4.
Cyclin E and CDK2 expression are enhanced in cisplatinresistant samples and further elevated in cisplatin-resistant
samples treated with palbociclib

To understand the phenomenon of unrestrained proliferation in palbociclib-treated tumors, we analyzed the
levels of cell cycle regulatory proteins by immunoblot.
Ofﬁcial journal of the Cell Death Differentiation Association

Levels of cyclin A, D, and E were analyzed, as well as
phosphorylated CDK2 and total CDK2 (Supplemental Fig.
5A, C, Fig. 4a), in tumor lysates that were either cisplatinsensitive (parental) or cisplatin-resistant. Cyclin D has
been most clearly linked to cisplatin resistance;46 however, we found no consistent pattern of alteration of
cyclins A or D in cisplatin-resistant samples (Supplemental Fig. 5B, D). In contrast, these blots demonstrated
that levels of cyclin E and phosphorylated CDK2 relative
to total CDK2 increased in cisplatin-resistant tumors
compared to parental lines (Fig. 4b).
To identify if palbociclib exposure in tumors might
hyperactivate the cyclin E-CDK2 pathway, subsequently
promoting palbociclib resistance in growing tumors, we
looked at the above regulatory protein levels in tumors
treated with palbociclib. Cisplatin-resistant tumors were
treated daily for 2 weeks with either vehicle or palbociclib,
and harvested 24 h after ﬁnal dosing. We observed that
cisplatin exposure caused increased cyclin E and CDK2
levels and activity (Fig. 4a, b), which has been previously
linked to cisplatin sensitivity47,48, but also that palbociclib

Robinson et al. Cell Death and Disease (2019)10:867
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Fig. 4 Cyclin E and CDK2 expression are enhanced in cisplatin-resistant samples and further elevated in cisplatin-resistant samples treated
with palbociclib. a Representative immunoblots of cyclin E, phosphor-CDK2, total CDK2, and actin for tumor cell lysates obtained from untreated
cisplatin naϊve (gray) and cisplatin-resistant xenografts (black). b Quantiﬁcation by photo densitometry was performed on bands using Image Lab
Software, cyclin E levels were normalized to β-actin loading control, and the ratio of p-CDK2/total CDK2 was calculated. c Representative
immunoblots of cisplatin-resistant tumor cell lysates after 14 days of daily treatment with either vehicle control (black) or palbociclib (blue). Lysates
were harvested 24 h after ﬁnal dosing. d Accompanying quantiﬁcation by photo densitometry. All quantiﬁcation is presented as mean ± SD. (*p ≤
0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001, by Student’s t-test)
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treatment further increased cyclin E and CDK2 activity
(Fig. 4c, d). In addition, tumor growth rates for all lines
treated with palbociclib or control were equivalent (Supplemental Fig. 5E).
Increased c-Myc is a mediator of cisplatin- as well as
palbociclib-resistance

c-Myc is an established mediator of cisplatin resistance49–51, and is also known to upregulate cyclin E52,53.
Therefore, we compared the level of c-Myc in cisplatinresistant versus parental tumors and found it to be signiﬁcantly higher in the cisplatin-resistant lysates (Fig. 5a,
b). To address whether this upregulation of c-Myc was an
early or late event, we tested for c-Myc expression at early
and late timepoints and found the induction to occur
early in the process, by day 7 of cisplatin exposure (Supplemental Fig. 6). c-Myc is also linked to cell cycle progression by inhibiting the expression of p21, a protein that
dephosphorylates and tags Rb for degradation. Based on
this, we hypothesized that the bromodomain inhibitor
JQ1, which is effective at inhibiting c-Myc54,55, might be
effective in cisplatin- and palbociclib-resistant tumors. In
vivo, neither palbociclib nor JQ1 as single agents were
able to markedly overcome the resistance phenotype
conferred by prior exposure to cisplatin, though JQ1 did
exhibit a signiﬁcant difference from vehicle control (Fig.
5c). Combination of JQ1 and palbociclib was sufﬁcient to
cause a signiﬁcant reduction in tumor volume that began
after 2 weeks of treatment (Fig. 5c). We hypothesized that
increased c-Myc, either due to baseline levels in cisplatinresistant cells or by palbociclib treatment, might be
responsible for this delay in effect. Therefore, a subset of
mice were pre-treated with JQ1 for 7 days before daily
treatment with palbociclib commenced, in an attempt to
reduce the delay. We found that JQ1 pre-treatment did
not change the timing or efﬁcacy of the combination,
suggesting that the delay in efﬁcacy was as a result of a
natural adaptation to palbociclib treatment (Fig. 5c).
Furthermore, we were able to show that this combination
of JQ1 and palbociclib is synergistic in both parental and
cisplatin-resistant cell lines (Supplemental Fig. 7). The
only points corresponding with antagonism are associated
with the lowest concentration of JQ1 that was used to
treat SCC1 and SCC25 cisplatin-resistant cell lines (Supplemental Table 1).
To understand the underlying mechanism, we probed
tumor lysates of single agent or combination treatment
(Fig. 5d) and found that c-Myc expression was suppressed
by JQ1 (Fig. 5e), and that treatment with JQ1 re-expressed
p21 in this system (Fig. 5f). Single agent treatments had
varying effects on Rb phosphorylation, with palbociclib
increasing Rb phosporylation, while treatment with JQ1
resulted in modest a decrease to Rb phosphorylation.
Importantly, in the combination of JQ1 and palbociclib,
Ofﬁcial journal of the Cell Death Differentiation Association
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activation of Rb was more clearly achieved through the
dual action of palbociclib- and p21-mediated (Fig. 5f) Rb
dephosphorylation (Fig. 5g). These combination results
provide rational for a strategy to mitigate the platinuminduced palbociclib resistance with the emerging class of
BET bromodomain inhibitors.

Discussion
HPV-negative head and neck squamous cell carcinoma
(HNSCC) are a subset of tumors resulting from tobaccorelated exposure or viral infection. Cisplatin is the most
effective chemotherapy for the treatment of these cancers,
but there is a high rate of clinical failure of cisplatin due to
inherent or acquired resistance56. Unexpectedly, Phase 1
clinical trial data utilizing palbociclib identiﬁed that palbociclib has decreased activity in cisplatin-resistant
HNSCC, suggesting a signaling pathway linking the two
therapies and driving potential resistance to treatment.
Understanding the biological shifts that these ﬁrst-line
therapies enact in cancer will allow for the development,
sequencing, and greater utilization of targeted therapies.
HNSCC is characterized by loss of p16, a tumor suppressor protein that restrains the activity of cyclindependent kinases 4/6 (CDK4/6), and allows for the
hyperphosphorylation of Rb. In normal tissue, the active
state of Rb sequesters E2F transcription factors, thereby
preventing cell cycle progression. Rb becomes inactivated
through a stepwise process of phosphorylation by cyclindependent kinases; initial phosphorylation occurs through
the complex of CDK4/6-cyclin D1, with further phosphorylation occurring by the complex of CDK2-cyclin E.
Following hyperphosphorylation, Rb releases E2F, which
then acts as a transcription factor to drive cell cycle
progression to S-phase (Fig. 6a). Palbociclib interrupts
this process at the ﬁrst step, inhibiting the activity of
CDK4/6/cyclin D1 and blocking further phosphorylation
of Rb (Fig. 6b). Importantly, the CAL27 cell-line has been
shown to have a truncating mutation in SMAD444, which
can cause aberrant activation of the CDK4 pathway57,
downregulation of the TGF-β pathway, and subsequent
resistance to palbociclib treatment58 and other CDK4
inhibitors59. This may explain the limited efﬁcacy of palbociclib in CAL27, and further emphasizes the importance of identifying therapies that make palbociclib
treatment more effective.
Cyclin E has been shown to overcome the antiproliferative activity of palbociclib in Rb positive cells
in vitro, as its cognate kinase CDK2 can inactivate Rb and
promote cell cycle progression29,60. We observed cyclin E
overexpression and hyperactivation of CDK2 in the
cisplatin-resistant lines. Recent studies have implicated
CDK2 as a potential mediator of DNA damage resistance61,62. Therefore, upregulation of cyclin E and pCDK2 in cisplatin-resistant cells may contribute to the

Robinson et al. Cell Death and Disease (2019)10:867

Page 8 of 13

Fig. 5 Cisplatin-resistant lines display up-regulated c-Myc expression and treatment with BET family protein inhibitor synergizes with
Palbociclib treatment. a Representative immunoblots of c-Myc and actin for tumor cell lysates harvested from parental and cisplatin-resistant
xenografts after 48 h of treatment with palbociclib. b Quantiﬁcation of c-Myc and actin for tumor cell lysates harvested from parental (gray) and
cisplatin-resistant (black) xenografts by photo densitometry was performed on bands using Image Lab Software, and normalized to β-actin loading
control for c-Myc. c Tumor growth curves for cisplatin-resistant xenografts treated daily with vehicle (black), single agent palbociclib at 70 mg/kg
(red), single agent JQ1 at 70 mg/kg (blue), combination therapy (green), or combination therapy pre-treated with JQ1 for the ﬁrst 7 days with
palbociclib added daily starting at day 7 (purple). n = 5 per group, summarized as mean ± SEM. d Representative immunoblots of c-Myc, p21, p-Rb,
total Rb, and actin for tumor cell lysates harvested from xenografts treated with vehicle (black), palbociclib (blue), JQ1 (yellow), or combination
therapy (green) after 28 days of treatment. e Quantiﬁcation by photo densitometry normalized to β-actin loading control for c-Myc. f Quantiﬁcation
by photo densitometry normalized to β-actin loading control for p21. g Calculation by photo densitometry normalized to β-actin loading control of
the ratio of p-Rb/total Rb. All quantiﬁcation is presented as mean ± SD. (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001, by Student’s t-test)

DNA damage response phenotype observed in these cells.
Therefore, the upregulation of cyclin E after cisplatin
exposure was an unexpected ﬁnding in our model system.
However, our data is consistent with reports that cisplatin
exposure can activate CDK2, promoting the phosphorylation of Rb and the subsequent release of E2F for continued cell cycle progression63 (Fig. 6c).

Ofﬁcial journal of the Cell Death Differentiation Association

The ability of oncogenes and tumor suppressor genes to
mediate resistance to cytotoxic chemotherapy is well
established. Early experiments with p53 loss of function
revealed a clear effect on chemoresistance64,65. Subsequently, c-Myc was found to be a driver of cisplatin-speciﬁc
resistance49–51. Our data was consistent with these observations, showing that c-Myc is signiﬁcantly upregulated in
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Fig. 6 Proposed model of JQ1 and palbociclib activity in cisplatin-sensitive and resistant cell lines. a HNSCC cell at baseline. b HNSCC cell
sensitive to cisplatin. c Cisplatin resistance confers palbociclib resistance. d JQ1 combined with palbociclib overcomes cisplatin resistance

cisplatin-exposed cells. To this end, we utilized the BET
bromodomain inhibitor JQ1 to inhibit c-Myc, in conjunction with palbociclib treatment. The inhibition of c-Myc
allows for the re-expression of p21, driving the dephosphorylation of Rb. This overcomes the activity of CDK2cyclin E and augments the efﬁcacy of palbociclib (Fig. 6d).
We were able to identify synergy between palbociclib and
Ofﬁcial journal of the Cell Death Differentiation Association

JQ1, showing that the combination of these therapies can
overcome cisplatin resistance and be more effective than
either agent alone. This provides a pre-clinical rationale for
future clinical trial development66. It is likely that strategy
using dual BET bromodomain with a CDK4/6 inhibitory
strategy may be useful in treating a signiﬁcant percentage of
patients with cisplatin-resistant HNSCC.
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Importantly, the relevance of these ﬁndings can be
attributed to other cisplatin-resistant cancers. Bromodomain inhibitors such as JQ1 have been shown to downregulate MYC expression in MYC-ampliﬁed tumors,
which sensitizes ovarian cancer cells to platinum-based
therapy67. In addition, the combination of JQ1 with cisplatin in ovarian cancer cells has shown increased survival
and decreased tumor outgrowth68,69. These ﬁndings
highlight the importance of identifying a synergistic
treatment that can overcome the resistance phenotype in
HNSCC and other platinum-resistant cancers.
This data suggests that further exploration into the
mechanism by which c-Myc is upregulated will be
necessary in order to fully understand the role of p21 and
Rb in the response to palbociclib and JQ1. If modiﬁcations
to SMAD4 and other factors in the CDK4 pathway have a
role to play in the upregulation of c-Myc, this could
stratify patients that could beneﬁt from combination
therapy. Noting the effect that prior EGFR treatment has
within this system will also be useful to study, as this data
was based on a clinical trial where most of the patients
were exposed to cetuximab. Additionally, we show that
palbociclib treatment reduces levels of total Rb in parental
and cisplatin-resistant cell lines. This is an important area
for future study, as the mechanism of total Rb reduction
may be a consequence of G1 arrest, as previously reported70, further implicating palbociclib as a cell cycle arrest
agent. Finally, CD31 staining showed a marked decrease
in angiogenesis in palbociclib-treated tumors compared to
vehicle control (Supplemental Fig. 4). This partially
explains the discordance in our in vitro versus in vivo
models. Future work exploring the role of the microenvironment in response to cisplatin resistance could
yield new avenues for therapeutic exploration.
A major limitation of this research is the cisplatinresistant cell lines that were utilized. The cell lines were
created by increasing concentrations of cisplatin treatment, rather than deriving cell lines from cisplatinresistant patients or creating a resistance model in vivo.
Furthermore, the microenvironment may play a strong
role in tumor response to combination treatment, suggesting that there may be differences in the biology of
cisplatin-resistant tumors that develop resistance in vivo,
in the presence of microenvironmental factors.

NY 15140122), and Hydrocortisone (400 ng/mL) (Sigma
H-0888). Cells were regularly passaged with 0.05% Trypsin/EDTA (500 mg/ml Trypsin, 200 mg/ml EDTA) (Life
Technologies, Grand Island, NY). All lines were regularly
tested for mycoplasma.

Materials and methods

Immunoblot analysis

Cell line maintenance

For xenografted tumor protein expression, three tumor
portions per treatment group were homogenized using
pestles and lysed in RIPA buffer for 20 min before sonication, followed by centrifugation for 10 min at 4 °C, and
supernatant collection. Total protein concentrations were
determined by Quick Start™ Bradford Assay (BioRad). In
all, 40 µg of protein lysate were added per sample, diluted
in millipure H2O to 20 µL, and diluted further with 5x

UM-SCC1 (referred to as SCC1, provided by the University of Michigan), SCC25 (ATCC), and Cal27 (ATCC)
cell lines were cultured at 37 °C in 5% CO2, in Dulbecco’s
Modiﬁed Eagle Medium/F12 Ham’s Nutrient Mix
(DMEM/F12) (Gibco #11330–032) supplemented with
10% FBS (Gibco #16140-071), Penicillin-Streptomycin
100 × (10,000 U/mL) (Life Technologies, Grand Island,
Ofﬁcial journal of the Cell Death Differentiation Association

Cisplatin-resistant line generation

Cell lines were exposed to one quarter of the initial IC50
concentration of cisplatin for 1 week, then allowed to
recover until normal growth resumed. Cycles of increasing drug concentration were applied to cell lines until
conﬁrmed resistance by Alamar blue assay.
Xenograft studies

Mouse xenograft experimental protocols were approved
by the Institutional Animal Care and Use Committee
(IACUC) at Washington University in St. Louis. Animals
were maintained and evaluated under pathogen-free
conditions following IACUC guidelines (St. Louis, MO).
Athymic nude mice (4–6-week-old females) were
obtained from Jackson Laboratories (Bar Harbor, ME). A
suspension of 2.0 × 106 cells was injected subcutaneously
into both ﬂanks of each mouse. Length and width of
tumors were measured several times per week, and
volumes were calculated using the formula (length x
width2)/2. Tumors were allowed to reach an average
volume of 200 mm3 before being randomly separated into
treatment groups. Mice were treated with vehicle control,
palbociclib in 0.05 N lactic acid by oral gavage daily at
70 mg/kg body weight, or (+) JQ1 in 5% DMSO, 10% 2Hydroxypropyl-β-cyclodextrin by intraperitoneal injection at 70 mg/kg body weight daily. Five mice per treatment group were utilized for all animal studies, with no
pre-determined size estimate. Investigators were not
blinded to mouse treatment conditions at time of measurement. Mice were killed according to IACUC approved
protocol upon reaching two centimeters diameter in one
dimension, or 1 day after last treatment. Tumor material
was harvested for (1) protein analyses by immunoblot
after snap freezing in liquid nitrogen, and (2) histological
studies by formalin ﬁxation. Tumor growth curves are
summarized as mean ± SEM, with similar variance
between all groups being compared. (*p ≤ 0.05, **p ≤ 0.01,
***p ≤ 0.001, ****p ≤ 0.0001, by Student’s t-test).
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SDS-PAGE Loading Buffer. Samples were boiled at 95 °C
for 5 min and ran through an SDS-PAGE gel. Samples
were electrotransferred onto 0.2 µm PVDF membranes.
Membranes were blocked with 5% milk in PBS-0.1%
Tween20 for 30 min at room temperature. Primary antibodies diluted in 3% BSA, 0.02% NaN3 solution were
incubated overnight on a rocker at 4 °C. After primary
antibody incubation, membranes were washed three times
in 1x PBS-0.1% Tween20 for 8 min each. Species-speciﬁc
HRP conjugated secondary monoclonal antibodies were
diluted in 5% milk in 1 × 0.1% Tween20 at a concentration
of 1:5000 and incubated for 1 h at room temperature.
After secondary antibody incubation, membranes were
washed three times in 1 × 0.1% Tween20 for 8 min each.
SuperSignal West Femto or Dura Maximum Sensitivity
Substrate (Thermo) was used for visualization. Unused
lysates were stored at −80 °C. Images were acquired using
Chemidoc XRS + imaging system and Image Lab Software. The antibodies as listed: Cell Signaling: anti-p-Rb
#9307, anti-Cyclin E (he12) #4129, anti-p-CDK2 #2561,
anti-Cyclin D1 #2978, anti-p21 #2947. R&D: anti-CDK2
AF4654, anti-Cyclin A2 AF5999. Abcam: anti-c-Myc
ab32072, anti-Rb ab85607. Sigma: anti-β-Actin A1978.
Quantiﬁcation of western blots are summarized as mean
± SD, with similar variance between all groups being
compared. (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤
0.0001, by Student’s t-test).
Cell cycle analysis

For cell cycle analysis, 1 × 106 cells were treated with
palbociclib for 24 h. Media was removed and cells were
trypsinized and collected for analysis. PI staining solution
was made using 0.1% sodium citrate, 0.03% NP40,
0.02 mg/mL RNase A, and 25 μg/mL propidium iodide.
Cells were resuspended in 350 μL of PI staining solution
(for a ﬁnal concentration of 1 mg/mL PI) and incubated
for 20 min at 4 °C. Staining was analyzed by ﬂuorescence
activated cell sorting (FACS) using a BD FACScan ﬂow
cytometer. In total, 10,000 events were captured and
analyzed using the cell cycle analysis program in FlowJo
(version 10) analysis software (Becton, Dickinson, and
Company). This analysis was conducted in triplicate with
biological replicates. Quantiﬁcation of analysis is summarized as mean ± SD, with similar variance between all
groups being compared. (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001,
****p ≤ 0.0001, by Student’s t-test).
JQ1 and palbociclib cell death and synergy studies in vitro

Cells were plated at 4–6 × 103 cells per well in 96-well
plates, depending on cell line. The following day, media
was changed to media supplemented with DMSO, Palbociclib, JQ1, or combination. Doses were dependent on
cell line. For cell death for IC50, Alamar blue diluted 1:10
in media was added, and plates were incubated 2–3 h
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before analysis by spectrophotometry. For synergy, plates
were loaded into IncuCycte Zoom platform and assayed
for 72 h. Proliferation data was determined by percent
conﬂuence readout and converted to percent growth
inhibition compared to vehicle control, and cell death was
measured by YOYO-1 Iodide. All assays were conducted
in triplicate with biological replicates. CalcuSyn software
(Cambridge, UK) was utilized to measure combination
index and Graphpad Prism 8 software was utilized for
statistical analysis. Quantiﬁcation of analysis is summarized as mean ± SD, with similar variance between all
groups being compared. (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001,
****p ≤ 0.0001, by Student’s t-test).
DNA damage comet assay

Cells were plated at 2 × 105 cells per well in 6-well
plates. The following day, one hour after treatment conditions, cells were trypsinized and centrifuged in 15 mL
tubes prior to irradiation. Cells were treated with either 10
gray or 30 gray ionizing radiation depending on line, using
the Small Animal Radiation Research Platform (SARRP)
by xStrahl. Cells were then assayed using Trevigen Comet
Assay (4252-50-K) according to the Trevigen protocol for
alkaline conditions. DNA was stained using SYBR-Green
ﬂuorescent dye and visualized on an Olympus IX70
microscope with an Olympus DP72 camera using a ×20
objective lens. CellSens Entry software was used for capturing images. OpenComet plugin from ImageJ was used
to analyze the resulting comets. All assays were conducted
in triplicate with biological replicates, and 40 images were
collected per run. Quantiﬁcation of analysis is summarized as mean ± SD, with similar variance between all
groups being compared. (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001,
****p ≤ 0.0001, by Student’s t-test).
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